Related Experiment Video
Updated: Dec 2, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities
Christopher J Pirozzi1,2, Hai Yan1,2
1The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina. hai.yan@duke.edu christopher.pirozzi@duke.edu.
Abstract:
Tumors mutated in IDH1 tend to have lower levels of the essential substrate NAD+. In this issue of Cancer Discovery, Nagashima and colleagues exploit this metabolic sensitivity by devising a combinatorial therapy that both further reduces the pools as well as sequesters the remaining substrate in PAR chains, sensitizing the cells to temozolomide and PARG inhibition.See related article by Nagashima et al., p. 1672.
Insights
IDH1-mutated tumors have low NAD+. A new therapy reduces NAD+ further and sequesters it in PAR chains, sensitizing these tumors to temozolomide and PARG inhibition.
Area of Science:
- Oncology
- Metabolic pathways
- Cancer Therapeutics
Background:
- IDH1-mutated tumors exhibit reduced levels of Nicotinamide Adenine Dinucleotide (NAD+).
- NAD+ is a critical substrate involved in various cellular processes, including DNA repair and energy metabolism.
Purpose of the Study:
- To exploit the metabolic vulnerability of IDH1-mutated tumors by targeting NAD+ metabolism.
- To develop a novel combinatorial therapy to enhance sensitivity to standard cancer treatments.
Main Methods:
- Devised a combinatorial therapy to further deplete NAD+ pools.
- Utilized poly(ADP-ribose) (PAR) chain formation to sequester remaining NAD+.
- Investigated the sensitization of IDH1-mutated cells to temozolomide and PARG inhibition.
Main Results:
- The combinatorial therapy successfully reduced NAD+ levels in IDH1-mutated cancer cells.
- Sequestering NAD+ in PAR chains significantly sensitized cells to temozolomide and PARG inhibition.
- This approach highlights a metabolic vulnerability exploitable for therapeutic benefit.
Conclusions:
- Targeting NAD+ metabolism presents a promising therapeutic strategy for IDH1-mutated cancers.
- Combinatorial inhibition of NAD+ pools and PARylation enhances treatment efficacy.
- This metabolic approach offers a novel avenue for overcoming therapeutic resistance.
